Skip to content

BRNS - Barinthus Biotherapeutics plc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchB

Barinthus Biotherapeutics plc

BRNS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

B

BRNSBarinthus Biotherapeutics plc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $1.83
52-wk low: $0.51
Prev close: $1.25
Mkt cap: $24.6M
Beta: -0.39
P/S: 3.8x

Smart money

2 funds hold a position.

Real smart money

Funds holding this stock

2 holders

Combined position$67K

CI
Citadel
Ken Griffin · Q2 2026 13F
$51K
position
JS
Jim Simons
Q2 2026 13F

Earnings

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $25M

Valuation

P/S3.80
P/B0.46

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: BRNS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $24.60M
Beta: -0.39

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

0.5x

Profit margin

+0.0%

Op margin

+0.0%

ROE

-52.4%

$17K

position

Coverage gaps for BRNS

No recent insider trade
No recent Congress trade
No recent market-voice mention

The latest quarter is still settling.

A verdict appears once the reported figure is final

Next report

What the street expects next

-52.4%

ROA-19.0%

Growth

Beta-0.39